Lifecore Biomedical Stock Performance
| LFCR Stock | 6.98 0.08 1.13% |
The company secures a Beta (Market Risk) of 3.05, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lifecore Biomedical will likely underperform. At this point, Lifecore Biomedical has a negative expected return of -0.19%. Please make sure to verify Lifecore Biomedical's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Lifecore Biomedical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Lifecore Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest inconsistent performance, the Stock's fundamental indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (1.79) | Five Day Return (5.97) | Year To Date Return 2.93 | Ten Year Return (40.60) | All Time Return (46.24) |
1 | Acquisition by Houde Lovas Katrina of 19506 shares of Lifecore Biomedical subject to Rule 16b-3 | 07/15/2025 |
2 | Disposition of 9554 shares by Barbarosh Craig A. of Lifecore Biomedical subject to Rule 16b-3 | 07/30/2025 |
3 | Lifecore Q4 Revenue Beats 3 | 08/08/2025 |
4 | CDMO Leader Lifecore Biomedical Announces Triple Conference Schedule Including Morgan Stanley Healthcare - Stock Titan | 09/02/2025 |
5 | Lifecore Biomedical Now Covered by KeyCorp | 09/04/2025 |
6 | Whats the beta of Lifecore Biomedical Inc. stock - 2025 Top Gainers Expert-Curated Trade Recommendations - | 09/05/2025 |
7 | Disposition of 5653 shares by Lake Ryan David of Lifecore Biomedical at 7.15 subject to Rule 16b-3 | 09/12/2025 |
8 | Gap Down Is Lifecore Biomedical Inc. a good ESG investment - July 2025 Analyst Calls Community Consensus Trade Alerts - khodrobank.com | 09/19/2025 |
9 | Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 09/23/2025 |
10 | LIFECORE SHAREHOLDER ALERT Kaskela Law LLC Announces Investigation of Lifecore Biomedical, Inc.and Encourages Long-Term Investors to Contact the Firm LFCR | 10/01/2025 |
| Begin Period Cash Flow | 8.5 M | |
| Total Cashflows From Investing Activities | -6.4 M |
Lifecore Biomedical Relative Risk vs. Return Landscape
If you would invest 819.00 in Lifecore Biomedical on July 8, 2025 and sell it today you would lose (121.00) from holding Lifecore Biomedical or give up 14.77% of portfolio value over 90 days. Lifecore Biomedical is currently does not generate positive expected returns and assumes 3.442% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Lifecore, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lifecore Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lifecore Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lifecore Biomedical, and traders can use it to determine the average amount a Lifecore Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LFCR |
Estimated Market Risk
| 3.44 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lifecore Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lifecore Biomedical by adding Lifecore Biomedical to a well-diversified portfolio.
Lifecore Biomedical Fundamentals Growth
Lifecore Stock prices reflect investors' perceptions of the future prospects and financial health of Lifecore Biomedical, and Lifecore Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lifecore Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0304 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 387.07 M | ||||
| Shares Outstanding | 37.47 M | ||||
| Price To Book | 197.99 X | ||||
| Price To Sales | 2.03 X | ||||
| Revenue | 128.87 M | ||||
| Gross Profit | 40.3 M | ||||
| EBITDA | (38.72 M) | ||||
| Net Income | (38.72 M) | ||||
| Total Debt | 132.17 M | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (206 K) | ||||
| Earnings Per Share | (1.27) X | ||||
| Market Capitalization | 261.52 M | ||||
| Total Asset | 239.34 M | ||||
| Retained Earnings | (205.24 M) | ||||
| Working Capital | 55.5 M | ||||
About Lifecore Biomedical Performance
Assessing Lifecore Biomedical's fundamental ratios provides investors with valuable insights into Lifecore Biomedical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Lifecore Biomedical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 133.07 | 24.33 | |
| Return On Tangible Assets | (0.17) | (0.02) | |
| Return On Capital Employed | (0.19) | 0.02 | |
| Return On Assets | (0.16) | (0.01) | |
| Return On Equity | (0.82) | (0.03) |
Things to note about Lifecore Biomedical performance evaluation
Checking the ongoing alerts about Lifecore Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lifecore Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lifecore Biomedical generated a negative expected return over the last 90 days | |
| Lifecore Biomedical has high historical volatility and very poor performance | |
| Lifecore Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 128.87 M. Net Loss for the year was (38.72 M) with profit before overhead, payroll, taxes, and interest of 40.3 M. | |
| Lifecore Biomedical generates negative cash flow from operations | |
| About 55.0% of the company shares are owned by institutional investors | |
| Latest headline from thefly.com: MAIA Biotechnology announces 2.25M private placement MAIA |
- Analyzing Lifecore Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lifecore Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Lifecore Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lifecore Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lifecore Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lifecore Biomedical's stock. These opinions can provide insight into Lifecore Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.